Nurix Therapeutics Inc. (NASDAQ:NRIX) went up by 14.29% from its latest closing price compared to the recent 1-year high of $37.42. The company’s stock price has collected 9.88% of gains in the last five trading sessions.
Is It Worth Investing in Nurix Therapeutics Inc. (NASDAQ :NRIX) Right Now?
Opinions of the stock are interesting as 9 analysts out of 10 who provided ratings for Nurix Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $41.30, which is $30.18 above the current price. NRIX currently public float of 43.36M and currently shorts hold a 11.64% ratio of that float. Today, the average trading volume of NRIX was 539.94K shares.
NRIX’s Market Performance
NRIX stocks went up by 9.88% for the week, with a monthly jump of 11.09% and a quarterly performance of -23.73%, while its annual performance rate touched -61.58%. The volatility ratio for the week stands at 9.30% while the volatility levels for the past 30 days are set at 10.62% for Nurix Therapeutics Inc. The simple moving average for the period of the last 20 days is 10.85% for NRIX stocks with a simple moving average of -48.85% for the last 200 days.
Analysts’ Opinion of NRIX
Many brokerage firms have already submitted their reports for NRIX stocks, with Wells Fargo repeating the rating for NRIX by listing it as a “Overweight.” The predicted price for NRIX in the upcoming period, according to Wells Fargo is $25 based on the research report published on May 31st of the current year 2022.
Wells Fargo, on the other hand, stated in their research note that they expect to see NRIX reach a price target of $28. The rating they have provided for NRIX stocks is “Equal Weight” according to the report published on February 10th, 2022.
H.C. Wainwright gave a rating of “Buy” to NRIX, setting the target price at $62 in the report published on December 29th of the previous year.
NRIX Trading at 1.13% from the 50-Day Moving Average
After a stumble in the market that brought NRIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.29% of loss for the given period.
Volatility was left at 10.62%, however, over the last 30 days, the volatility rate increased by 9.30%, as shares surge +11.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.54% lower at present.
During the last 5 trading sessions, NRIX rose by +9.88%, which changed the moving average for the period of 200-days by -65.20% in comparison to the 20-day moving average, which settled at $10.09. In addition, Nurix Therapeutics Inc. saw -61.59% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NRIX starting from Hansen Gwenn, who sale 1,098 shares at the price of $11.75 back on May 02. After this action, Hansen Gwenn now owns 17,151 shares of Nurix Therapeutics Inc., valued at $12,902 using the latest closing price.
Wolff Stefani, the EVP and COO of Nurix Therapeutics Inc., sale 330 shares at $11.75 during a trade that took place back on May 02, which means that Wolff Stefani is holding 632 shares at $3,878 based on the most recent closing price.
Stock Fundamentals for NRIX
Current profitability levels for the company are sitting at:
- -396.26 for the present operating margin
- +79.56 for the gross margin
The net margin for Nurix Therapeutics Inc. stands at -393.93. Equity return is now at value -38.10, with -28.10 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.70.